LH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Labcorp Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $8,052 Mil. Labcorp Holdings's Total Assets for the quarter that ended in Dec. 2024 was $18,379 Mil. Therefore, Labcorp Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was 0.44.
The historical rank and industry rank for Labcorp Holdings's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of Labcorp Holdings was 0.50. The lowest was 0.35. And the median was 0.43.
The historical data trend for Labcorp Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
0.47 | 0.50 | 0.50 | 0.47 | 0.44 |
Labcorp Holdings Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Equity-to-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.47 | 0.48 | 0.48 | 0.44 | 0.44 |
For the Diagnostics & Research subindustry, Labcorp Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Labcorp Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Labcorp Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
Equity to Asset (A: Dec. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 8052.2 | / | 18379 | |
= | 0.44 |
Labcorp Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as
Equity to Asset (Q: Dec. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 8052.2 | / | 18379 | |
= | 0.44 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings (NYSE:LH) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Labcorp Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Kerrii B Anderson | director | WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017 |
Mark S Schroeder | officer: EVP, President-Diagnostics Lab | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Van Der Vaart Sandra D | officer: SVP, Global General Counsel | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Amy B. Summy | officer: EVP, Chief Marketing Officer | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Adam H Schechter | director | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Dwight Gary Gilliland | director | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Glenn A Eisenberg | officer: Chief Financial Officer, EVP | P O BOX 1017, CHARLOTTE NC 28201-1017 |
Lance Berberian | officer: SVP, Chief Information Officer | |
Peter J Wilkinson | officer: SVP, Chief Accounting Officer | C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401 |
Paul Rothman | director | 6 MEADOW ROAD, BALTIMORE MD 21212 |
Paul R Kirchgraber | officer: CEO, Covance Drug Development | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Megan D. Bailey | officer: EVP, Chief Strategy Officer | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Jonathan P. Divincenzo | officer: EVP, Pres, Central Labs & Intl | 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
Anita Z Graham | officer: EVP, CHRO | C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431 |
Thomas Pike | officer: Pres & CEO Clinical Business | C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601 |
From GuruFocus
By PRNewswire • 12-17-2024
By PRNewswire • 02-06-2025
By GuruFocus News • 11-25-2024
By GuruFocus News • 11-19-2024
By GuruFocus News • 12-17-2024
By GuruFocus News • 02-27-2025
By GuruFocus News • 10-24-2024
By PRNewswire • 02-24-2025
By GuruFocus News • 01-08-2025
By GuruFocus News • 12-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.